Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease

Aim. This review study is aimed at characterizing the nutrition of patients with non-alcoholic fatty liver disease (NAFLD).

General findings. A high-calorie diet, followed even for a short period of time, can lead to an increase in the lipid content in hepatocytes and an increase in ALT values. These changes occur much earlier than weight gain, glucose metabolism disorders and other clinically obvious changes. So far, only the Mediterranean diet (or the Mediterranean type of food) has been scientifically confirmed as beneficial for human health. It is recommended for patients with NAFLD both by Russian and international clinical guidelines. The molecular mechanisms of beneficial effects on human health have been confirmed for such Mediterranean diet components as polyphenols, carotenoids, oleic acid, polyunsaturated fatty acids and dietary fiber. The enrichment of the Mediterranean diet with olive oil (+10 g) reduces the risk of diabetes mellitus by 40 %. The addition of Omega-3 fatty acids to food reduces the risk of hepatocellular cancer. A balanced ratio of omega 3 and omega 6 in the diet is more important than the absolute amount of individual fatty acids. Vegetables and fruit contain two main classes of antioxidants: polyphenols and carotenoids. In patients with NAFLD, they exhibit an anti-inflammatory and antifibrotic effect both in vivo and in vitro. Food produced from whole grain has a lower energy potential as compared to that produced from refined grain. Meat contains various nutrients, such as proteins, iron, zinc, B12 vitamin, as well as sodium, saturated fatty acids and cholesterol, which serve as risk factors for the development of NAFLD and other cardio-metabolic disorders. In this paper, we present a clinical observation of a 51-year-old patient with NAFLD and cardio-metabolic disorders. Practical recommendations are given on changes in his lifestyle and the choice of optimal therapy with the application of multifunctional drugs affecting all disease aspects.

Conclusion. The concepts of ‘correct or healthy’ nutrition and ‘lifestyle modification’ are increasingly attracting much attention both in terms of the prevention and treatment of liver diseases. Proper nutrition is important for a good life prognosis in patients with non-alcoholic fatty liver disease (NAFLD). 

1. http://weekjournal.ru/society/29815/.

2. Komova A.G., Mayevskaya M.V., Ivashkin V.T. Principles of effective out-patient diagnostics of diffuse liver diseasesRus J Gastroenterol Hepatol Colproctol. 2014;24(5):36–41 (In Rus.).

3. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Palgova L.K., Tsukanov V.V., Ushakova T.I. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Rus J Gastroenterol Hepatol Colproctol. 2015;25(6):31–41 (In Rus.).

4. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Tikhonov I.N., Shirokova Ye.N., Buyeverov A.O., Drapkina O.M., Shulpekova Yu.О., Tsukanov V.V., Mammayev S.N., Mayev I.V., Palgova L.K. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rus J Gastroenterol Hepatol Colproctol. 2016;26(2):24–42 (In Rus.).

5. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.

6. https://ritual.ru/poleznaya-informacia/articles/statistikasmertnosti-v-rossii/.

7. Lee Y.H., Kim K.J., Yoo M.E., Yoon H.J., Jo K., Youn J.C., et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J of Hepatol. 2018;68;764–72.

8. Sobrecases H., Lê K.A., Bortolotti M., Schneiter P., Ith M., Kreis R., Boesch C., Tappy L. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes&Metabolism. 2010;36(3):244–6.

9. Kechagias S., Ernersson Å., Dahlqvist O., et al. Fastfood-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut. 2008;57:649–54.

10. Albhaisi S., Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Research. 2018;7:F1000 Faculty Rev-720. DOI: 10.12688/ f1000research.14421.1

11. http://www.easl.eu/medias/cpg/pdf_files/NAFLD_ RU.pdf.

12. Zelber-Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936–49.

13. Panagiotakos D.B., Pitsavos C., Stefanidis C. Dietary patterns: A Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutrition, Metabolism and Cardiovascular Disease. 2006;16(8):559–68.

14. Trichopoulou A., Costacou T., Bamia Ch, Trichopoulou D. Adherence to a Mediterranean Diet and Survival in a Greek Population. N Engl J Med. 2003;348:2599–608.

15. Kim S., Haines P.S., Siega-Riz A.M., Popkin B.M. The Diet Quality Index-International (DQI-I) provides an effective tool for cross-national comparison of diet quality as illustrated by China and the United States. J Nutr. 2003;133:3476–84.

16. Fraser A., Abel R., Lawlor D.A., Fraser D., Elhayany A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia. 2008;51:1616–22.

17. Bozzetto L., Prinster A., Annuzzi G., et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35:1429–35.

18. Ryan M.C., Itsiopoulos C., Thodis T., et al. The mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with nonalcoholic fatty liver disease. J Hepatol. 2013;59:138–43.

19. Kontogianni M.D., Tileli N., Margariti A., et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33:678–83.

20. Trovato F.M., Catalano D., Martines G.F., Pace P., Trovato G.M. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr. 2015;34:86–8.

21. Chan R., Wong V.W., Chu W.C., et al. Diet-quality scores and prevalence of nonalcoholic fatty liver disease: a population study using proton-magnetic resonance spectroscopy. PLoS One. 2015;10:e0139310.

22. Aller R., Izaola O., de la Fuente B., de Luis Roman D.A. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr Hosp. 2015;32:2518–24.

23. Abenavoli L., Greco M., Nazionale I., et al. Effects of Mediterranean diet supplemented with silybin-vitamin Ephospholipid complex in overweight patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519–27.

24. Trovato F.M., Martines G.F., Brischetto D., Trovato G., Catalano D. Neglected features of lifestyle: their relevance in non-alcoholic fatty liver disease. World J Hepatol. 2016;8:1459–65.

25. Маевская М.В., Маевский Р.М. Еда как образ жизни. Рос журн гастроэнтерол гепатол колопроктол 2016;26(5):104–15 [Mayevskaya M.V., Mayevsky R.M. Food as a lifestyle Rus J Gastroenterol Hepatol Colproctol. 2016;26(5):104–15 (In Rus.)].

26. Buckland G., Mayen A.L., Agudo A., Travier N., Navarro C., Huerta J.M., et al. Olive oil intake and mortality within the Spanish population (EPIC-Spain). Am J Clin Nutr. 2012;96(1):142–9.

27. Lu W., Li S., Li J., et al. Effects of omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis. Gastroenterol Res Pract. 2016;2016:1459790.

28. Sawada N., Inoue M., Iwasaki M., et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology. 2012;142:1468–75.

29. Zárate R., el Jaber-Vazdekis N., Tejera N., Pérez J.A., Rodríguez C. Significance of long chain polyunsaturated fatty acids in human health. Clinical and Translational Medicine. 2017;6:25.

30. Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012;142:1026–32.

31. http://www.mayoclinic.org/healthy-lifestyle/nutritionand-healthy-eating/in-depth/mediterranean-diet/art20047801.

32. Khera A.V., Emdin C.A., Drake I., et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375:2349–58.

33. Simopuolos A.P. The importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med (Maywood). 2008;233(6):674–88.

34. Balukova E.V., Uspensky Yu.P. Essential phospholipids of the new generation in the complex therapy of dyslipidemia. Consilium Medicum. Gastroenterology. (App.) 2012;1:91–4 (In Rus.).

35. Gryshchenko E.B. Place of phospholipid drugs in modern therapeutic practice. Medical advice. 2013;3:52–7 (In Rus.).

36. Bakulin I.G., Sandler Yu.G. Hypolipidemic therapy and the liver. Med Vesti. 2012;17(1):43–51 (In Rus.).

37. Myazin R.G. Non-alcoholic liver disease: New treatment options. Meditsinsky Sovet. 2014; 13 (In Rus.).

38. Drapkina O.M., Zyatenkova E.V., Korneyeva O.N. Effect of polyunsaturated phospholipids on microcirculation, endothelial function and lipid spectrum in patients with high risk systemic hypertension and dyslipidemia. Med Vesti. 2013;18(1):47–55 (In Rus.).